日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

CLDN6 特异性 CAR-T 细胞联合扩增 RNA 疫苗治疗复发或难治性实体瘤:1 期 BNT211-01 试验

Andreas Mackensen #, John B A G Haanen #, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lüke, Nadine Kutsch, Fabian Müller, Eveline Smit, Peter Hillemanns, Panagiotis Karagia

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

结节性淋巴细胞为主型霍奇金淋巴瘤中 B 细胞受体对 Rothia mucilaginosa 的反应性

Lorenz Thurner, Natalie Fadle, Evi Regitz, Sophie Roth, Onur Cetin, Igor Age Kos, Simon Mauro Hess, Julia Bein, Rainer Maria Bohle, Martine Vornanen, Christer Sundström, Laurence De Leval, Enrico Tiacci, Peter Borchmann, Andreas Engert, Viola Poeschel, Gerhard Held, Eva C Schwarz, Frank Neumann, Kla

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

双特异性免疫配体 ULBP2-aCEA 将自然杀伤细胞重定向至肿瘤细胞,并显示出对结肠癌的强效抗肿瘤活性

Achim Rothe, Ron D Jachimowicz, Sven Borchmann, Marie Madlener, Jörg Keßler, Katrin S Reiners, Maike Sauer, Hinrich P Hansen, Roland T Ullrich, Sampurna Chatterjee, Peter Borchmann, Paul Yazaki, Thomas C Koslowsky, Andreas Engert, Lukas C Heukamp, Michael Hallek, Elke Pogge von Strandmann